It’s a pivotal moment for longevity science, the first opportunity for researchers to prove that epigenetic reprogramming — a technique that trains aging cells to act young again — can actually improve how people age in the real world.
On Tuesday, Boston-based biotech startup Life Biosciences announced that its first patient has been dosed with a cellular reprogramming injection, designed to reverse age-related diseases.
…
In this case, the injection went into one eyeball of a single person with glaucoma. … Over the next six months, scientists will be watching to see how well the technique works, while doctors keep an eye out for any safety issues.
Share this article
The company’s cofounder, Harvard geneticist David Sinclair, is one of the most well-known and controversial figures in longevity science. Sinclair, who’s no longer involved in the day-to-day operations at Life Biosciences, has been known for hyping up his own experimental anti-aging treatments that have never quite met expectations. But for all his misses, his ideas helped lay the foundation for this new trial, which, if successful, could be groundbreaking.
